PRESENTATION | Finance
4Q23 Wrap: Turning up
Winners, losers in biotech stock tiers in 4Q23
January 10, 2024 11:39 PM UTC
Biopharma stocks gained across all market cap tiers in 4Q23, though most did not erase losses in earlier quarters to finish the year in the black. Only the group that started 2023 between $5-$9.9 billion showed a median gain for the full year.
Stocks starting at $10 billion or more rose a median of 7% in 4Q23, adding a combined $36.1 billion to their valuations. The megacap group had the worst full-year performance, however, falling 18% and losing a cumulative $38.5 billion...